Investor relations
Cinclus Pharma
Investors
Cinclus Pharma is a Swedish clinical stage pharma company developing small molecules for the treatment of gastric acid related diseases. Our lead candidate linaprazan glurate is being developed for treatment of severe gastroesophageal reflux disease (GERD).
Latest financial reports |
| Interim Report Jan-Mar 2025 |
| Cinclus Pharma Annual Report 2024 |
| Year End Report 2024 |
| Interim Report Jan – Sept 2024 |
Financial calendar |
| Q2 Report 2025 | 20 August 2025 | ||
| Q3 Report 2025 | 20 November 2025 | ||
| Year-end Report 2025 | 18 February 2026 |
